Theravance Biopharma, Inc. (NASDAQ:TBPH) Given a $55.00 Price Target at Cantor Fitzgerald

Theravance Biopharma, Inc. (NASDAQ:TBPH) received a $55.00 price objective from equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, October 25th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 91.17% from the stock’s current price.

Several other analysts have also issued reports on the stock. BidaskClub lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Evercore ISI initiated coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 target price for the company. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Theravance Biopharma has an average rating of “Hold” and an average price target of $41.86.

Shares of Theravance Biopharma (NASDAQ TBPH) traded up $0.96 during mid-day trading on Wednesday, reaching $28.77. 154,400 shares of the company’s stock were exchanged, compared to its average volume of 170,818. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 6.53. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44.

TRADEMARK VIOLATION NOTICE: This report was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/11/13/cantor-fitzgerald-analysts-give-theravance-biopharma-inc-tbph-a-55-00-price-target.html.

In related news, EVP Bradford J. Shafer sold 14,670 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now owns 134,327 shares in the company, valued at $4,133,241.79. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Frank Pasqualone purchased 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average price of $26.34 per share, with a total value of $105,360.00. Following the transaction, the senior vice president now owns 213,180 shares of the company’s stock, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. 6.10% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC lifted its holdings in Theravance Biopharma by 1.5% during the second quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 217 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 230 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Theravance Biopharma by 8.1% during the second quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 443 shares during the last quarter. Legal & General Group Plc lifted its holdings in Theravance Biopharma by 3.7% during the second quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 576 shares during the last quarter. Finally, Zacks Investment Management lifted its holdings in Theravance Biopharma by 4.6% during the second quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 959 shares during the last quarter. 84.54% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply